P114 Safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Phase 2 results from a phase 1/2 study
Year: 2012
Type: conference-abstract
Source: European Urology Supplements
Authors: D. Petrylak, J. Gandhi, W.R. Clark, E.I. Heath, J. Lin, W.K. Oh, D.B. Agus, B. Carthon, S. Moran, P. Mortimer, G. Liu
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2054554067